Fate Therapeutics (FATE)
(Real Time Quote from BATS)
$4.10 USD
+0.22 (5.67%)
Updated Sep 19, 2024 11:37 AM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Fate Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -160.93 | -281.72 | -212.15 | -173.39 | -98.15 |
Depreciation/Amortization & Depletion | 14.08 | 16.18 | 14.91 | 7.87 | 2.45 |
Net Change from Assets/Liabilities | 19.18 | -34.71 | 2.10 | -12.77 | 3.64 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -4.60 | 52.05 | 32.27 | 139.06 | 8.88 |
Net Cash From Operating Activities | -132.26 | -248.21 | -162.87 | -39.23 | -83.18 |
Property & Equipment | -6.15 | -35.57 | -50.70 | -4.93 | -7.40 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 118.82 | 202.32 | -273.32 | -156.14 | -150.06 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 112.67 | 166.75 | -324.02 | -161.08 | -157.45 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.09 | 9.21 | 453.13 | 282.35 | 164.93 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | -15.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.49 | 0.00 |
Net Cash from Financing Activities | 0.09 | 9.21 | 453.13 | 282.84 | 149.93 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -19.51 | -72.25 | -33.76 | 82.53 | -90.70 |
Cash at Beginning of Period | 76.56 | 148.81 | 182.57 | 100.04 | 190.74 |
Cash at End of Period | 57.05 | 76.56 | 148.81 | 182.57 | 100.04 |
Diluted Net EPS | -1.64 | -2.91 | -2.24 | -2.10 | -1.44 |
Fiscal Year End for Fate Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -86.43 | -48.00 | -160.93 | -116.81 | -71.64 |
Depreciation/Amortization & Depletion | 4.19 | 2.19 | 14.08 | 12.10 | 10.62 |
Net Change from Assets/Liabilities | -3.18 | 0.61 | 19.18 | 23.37 | 26.19 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 19.76 | 11.85 | -4.60 | -14.29 | -22.53 |
Net Cash From Operating Activities | -65.66 | -33.35 | -132.26 | -95.63 | -57.35 |
Property & Equipment | -0.14 | -0.09 | -6.15 | -5.97 | -5.41 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -35.92 | 17.40 | 118.82 | 73.28 | 47.91 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -36.06 | 17.31 | 112.67 | 67.31 | 42.51 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 94.82 | 95.49 | 0.09 | 0.27 | 0.27 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 1.94 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 96.76 | 95.49 | 0.09 | 0.27 | 0.27 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -4.95 | 79.45 | -19.51 | -28.05 | -14.58 |
Cash at Beginning of Period | 57.05 | 57.05 | 76.56 | 76.56 | 76.56 |
Cash at End of Period | 52.09 | 136.50 | 57.05 | 48.51 | 61.98 |
Diluted Net EPS | -0.33 | -0.47 | -0.45 | -0.46 | -0.54 |